Cited by 103Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology ResearchNeuroinflammation and Neurodegeneration Mechanisms

Calcineurin inhibition with FK506 ameliorates dendritic spine density deficits in plaque-bearing Alzheimer model mice

Open access
Rozkalne, Anete, Hyman, Bradley T., Spires-Jones, Tara L.·2011·Neurobiology of Disease

Abstract

Synapse loss is the strongest correlate of cognitive decline in Alzheimer's disease, and synapses are an attractive therapeutic target due to their plastic nature that allows for potential recovery with intervention. We have previously demonstrated in transgenic mice that form senile plaques that dendrites surrounding plaques become dystrophic and lose postsynaptic dendritic spines. Furthermore, we found strong evidence that plaque-associated dendritic changes are mediated by calcineurin, a calcium-dependent phosphatase involved in cell signaling, using in vitro models and genetically encoded inhibitors in mouse models. In this study, we pharmacologically inhibited calcineurin with FK506 treatment to test the hypothesis that calcineurin inhibition will allow recovery of plaque-associated synapse loss. We found that in plaque bearing transgenic mice, short term (1 week) FK506 treatment results in an amelioration of dendritic spine loss. We also observe an effect on spine morphology in wild-type mice with FK506 treatment. These data show that systemic FK506 administration, and hence calcineurin inhibition, may be neuroprotective for amyloid beta induced synaptic alterations.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2010.11.014

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Aβ-induced dendritic spine loss can be prevented with the calcineurin inhibitor FK506.

    “Aβ-induced dendritic spine loss can be prevented with the calcineurin inhibitor FK506.20”

    From Controlled Cortical Impact Results in an Extensive Loss of Dendritic Spines that Is Not Mediated by Injury-Induced Amyloid-Beta Accumulation (2013) · cites this paper as [20]

    The Discussion reports that seven days of FK506 rescued dendritic spine density in APP/PS1 mice and describes this as improving Aβ-induced spine loss. The study tested recovery of an existing deficit in plaque-bearing mice, not whether FK506 prevents spine loss from occurring. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rozkalne, A., Hyman, B. T., & Spires-Jones, T. L.
Affiliations
Harvard University (US)
Corresponding author
Hyman, Bradley T.
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2011-03
Volume
41
Issue
3
Pages
650-654
ISSN
0969-9961 (ISSN-L)
OpenAlex
W2035302673
Cited by
103
References
35
Citations by year
2026: 1 · 2025: 7 · 2024: 11 · 2023: 12 · 2022: 6 · 2021: 5 · 2020: 7 · 2019: 5 · 2018: 4 · 2017: 10 · 2016: 5 · 2015: 7 · 2014: 6 · 2013: 7 · 2012: 4
FWCI
3.68
Type
journal article
Language
en
Open access
Locations
  • Neurobiology of Disease (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
Funders
Alzheimer's Drug Discovery Foundation (AG08487, P50 AG005134)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
calcineurin inhibition, FK506, dendritic spine loss, Alzheimer's disease, amyloid plaques, synaptic loss, neuroprotection, transgenic mouse model, calcium-dependent phosphatase
MeSH terms
Alzheimer Disease, Animals, Disease Models, Animal, Mice, Transgenic, Tacrolimus, Dendritic Spines, Mice, Plaque, Amyloid, Calcineurin Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review